271 related articles for article (PubMed ID: 9926942)
1. The second BRCT domain of BRCA1 proteins interacts with p53 and stimulates transcription from the p21WAF1/CIP1 promoter.
Chai YL; Cui J; Shao N; Shyam E; Reddy P; Rao VN
Oncogene; 1999 Jan; 18(1):263-8. PubMed ID: 9926942
[TBL] [Abstract][Full Text] [Related]
2. BRCA1 physically associates with p53 and stimulates its transcriptional activity.
Zhang H; Somasundaram K; Peng Y; Tian H; Zhang H; Bi D; Weber BL; El-Deiry WS
Oncogene; 1998 Apr; 16(13):1713-21. PubMed ID: 9582019
[TBL] [Abstract][Full Text] [Related]
3. BRCA1 proteins are transported to the nucleus in the absence of serum and splice variants BRCA1a, BRCA1b are tyrosine phosphoproteins that associate with E2F, cyclins and cyclin dependent kinases.
Wang H; Shao N; Ding QM; Cui J; Reddy ES; Rao VN
Oncogene; 1997 Jul; 15(2):143-57. PubMed ID: 9244350
[TBL] [Abstract][Full Text] [Related]
4. c-Fos oncogene regulator Elk-1 interacts with BRCA1 splice variants BRCA1a/1b and enhances BRCA1a/1b-mediated growth suppression in breast cancer cells.
Chai Y; Chipitsyna G; Cui J; Liao B; Liu S; Aysola K; Yezdani M; Reddy ES; Rao VN
Oncogene; 2001 Mar; 20(11):1357-67. PubMed ID: 11313879
[TBL] [Abstract][Full Text] [Related]
5. Arrest of the cell cycle by the tumour-suppressor BRCA1 requires the CDK-inhibitor p21WAF1/CiP1.
Somasundaram K; Zhang H; Zeng YX; Houvras Y; Peng Y; Zhang H; Wu GS; Licht JD; Weber BL; El-Deiry WS
Nature; 1997 Sep; 389(6647):187-90. PubMed ID: 9296497
[TBL] [Abstract][Full Text] [Related]
6. A novel domain of BRCA1 interacts with p53 in breast cancer cells.
Buck M
Cancer Lett; 2008 Sep; 268(1):137-45. PubMed ID: 18501503
[TBL] [Abstract][Full Text] [Related]
7. Novel signaling molecules implicated in tumor-associated fatty acid synthase-dependent breast cancer cell proliferation and survival: Role of exogenous dietary fatty acids, p53-p21WAF1/CIP1, ERK1/2 MAPK, p27KIP1, BRCA1, and NF-kappaB.
Menendez JA; Mehmi I; Atlas E; Colomer R; Lupu R
Int J Oncol; 2004 Mar; 24(3):591-608. PubMed ID: 14767544
[TBL] [Abstract][Full Text] [Related]
8. Myc suppression of the p21(Cip1) Cdk inhibitor influences the outcome of the p53 response to DNA damage.
Seoane J; Le HV; Massagué J
Nature; 2002 Oct; 419(6908):729-34. PubMed ID: 12384701
[TBL] [Abstract][Full Text] [Related]
9. BRCA1 carries tumor suppressor activity distinct from that of p53 and p21.
Randrianarison V; Marot D; Foray N; Cabannes J; Méret V; Connault E; Vitrat N; Opolon P; Perricaudet M; Feunteun J
Cancer Gene Ther; 2001 Oct; 8(10):759-70. PubMed ID: 11687899
[TBL] [Abstract][Full Text] [Related]
10. ING1 represses transcription by direct DNA binding and through effects on p53.
Kataoka H; Bonnefin P; Vieyra D; Feng X; Hara Y; Miura Y; Joh T; Nakabayashi H; Vaziri H; Harris CC; Riabowol K
Cancer Res; 2003 Sep; 63(18):5785-92. PubMed ID: 14522900
[TBL] [Abstract][Full Text] [Related]
11. Transactivation of the p21 promoter by BRCA1 splice variants in mammary epithelial cells: evidence for both common and distinct activities of wildtype and mutant forms.
Lu M; Arrick BA
Oncogene; 2000 Dec; 19(54):6351-60. PubMed ID: 11175350
[TBL] [Abstract][Full Text] [Related]
12. BRCA1 signals ARF-dependent stabilization and coactivation of p53.
Somasundaram K; MacLachlan TK; Burns TF; Sgagias M; Cowan KH; Weber BL; el-Deiry WS
Oncogene; 1999 Nov; 18(47):6605-14. PubMed ID: 10597265
[TBL] [Abstract][Full Text] [Related]
13. Role of an ING1 growth regulator in transcriptional activation and targeted histone acetylation by the NuA4 complex.
Nourani A; Doyon Y; Utley RT; Allard S; Lane WS; Côté J
Mol Cell Biol; 2001 Nov; 21(22):7629-40. PubMed ID: 11604499
[TBL] [Abstract][Full Text] [Related]
14. Activation of the p21WAF1/CIP1 promoter independent of p53 by the histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA) through the Sp1 sites.
Huang L; Sowa Y; Sakai T; Pardee AB
Oncogene; 2000 Nov; 19(50):5712-9. PubMed ID: 11126357
[TBL] [Abstract][Full Text] [Related]
15. Induction of apoptosis by the p53-273L (Arg --> Leu) mutant in HSC3 cells without transactivation of p21Waf1/Cip1/Sdi1 and bax.
Kaneuchi M; Yamashita T; Shindoh M; Segawa K; Takahashi S; Furuta I; Fujimoto S; Fujinaga K
Mol Carcinog; 1999 Sep; 26(1):44-52. PubMed ID: 10487521
[TBL] [Abstract][Full Text] [Related]
16. Differential transcriptional activation by the N-terminal region of BRCA1 splice variants BRCA1a and BRCA1b.
Cui JQ; Wang H; Reddy ES; Rao VN
Oncol Rep; 1998; 5(3):585-9. PubMed ID: 9538156
[TBL] [Abstract][Full Text] [Related]
17. [Chromatin immunoprecipitation and its preliminary application for gene regulation].
Zhang Y; Cheng XK; Wu NH; Shen YF
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2004 Feb; 26(1):52-5. PubMed ID: 15052775
[TBL] [Abstract][Full Text] [Related]
18. Missense mutations of BRCA1 gene affect the binding with p53 both in vitro and in vivo.
Quaresima B; Faniello MC; Baudi F; Crugliano T; Di Sanzo M; Cuda G; Costanzo F; Venuta S
Oncol Rep; 2006 Oct; 16(4):811-5. PubMed ID: 16969499
[TBL] [Abstract][Full Text] [Related]
19. The BRCT domain is a phospho-protein binding domain.
Yu X; Chini CC; He M; Mer G; Chen J
Science; 2003 Oct; 302(5645):639-42. PubMed ID: 14576433
[TBL] [Abstract][Full Text] [Related]
20. Rb-associated protein 46 (RbAp46) inhibits transcriptional transactivation mediated by BRCA1.
Chen GC; Guan LS; Yu JH; Li GC; Choi Kim HR; Wang ZY
Biochem Biophys Res Commun; 2001 Jun; 284(2):507-14. PubMed ID: 11394910
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
